{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:15:40Z","timestamp":1786979740587,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"MH received a post-doctoral fellowship grant from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00198-021-05845-2","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T15:02:50Z","timestamp":1611241370000},"page":"1395-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9992-8663","authenticated-orcid":false,"given":"M.","family":"Hoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Skovlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. E.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Langhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"S\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Syversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Holvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"5845_CR1","doi-asserted-by":"publisher","unstructured":"(1993) Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646\u2013650. https:\/\/doi.org\/10.1016\/0002-9343(93)90218-e","DOI":"10.1016\/0002-9343(93)90218-e"},{"issue":"3","key":"5845_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 374(3):254\u2013262. https:\/\/doi.org\/10.1056\/NEJMcp1513724","journal-title":"N Engl J Med"},{"issue":"10169","key":"5845_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393(10169):364\u2013376. https:\/\/doi.org\/10.1016\/S0140-6736(18)32112-3","journal-title":"Lancet"},{"key":"5845_CR4","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Suttorp MJ, Motala A, Ewing B, Roth B, Shanman R, Timmer M, Shekelle PG (2012) Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville MD"},{"issue":"10","key":"5845_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M14-0317","volume":"161","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161(10):711\u2013723. https:\/\/doi.org\/10.7326\/M14-0317","journal-title":"Ann Intern Med"},{"key":"5845_CR6","doi-asserted-by":"publisher","first-page":"CD001155","DOI":"10.1002\/14651858.CD001155.pub2","volume":"1","author":"GA Wells","year":"2008","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155. https:\/\/doi.org\/10.1002\/14651858.CD001155.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"5845_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00198-020-05380-6","volume":"31","author":"O Strom","year":"2020","unstructured":"Strom O, Lauppe R, Ljunggren O, Spangeus A, Ortsater G, O'Kelly J, Akesson K (2020) Real-world effectiveness of osteoporosis treatment in the oldest old. Osteoporos Int 31(8):1525\u20131533. https:\/\/doi.org\/10.1007\/s00198-020-05380-6","journal-title":"Osteoporos Int"},{"issue":"1","key":"5845_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11657-018-0439-3","volume":"13","author":"AA Yusuf","year":"2018","unstructured":"Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C (2018) Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch Osteoporos 13(1):33. https:\/\/doi.org\/10.1007\/s11657-018-0439-3","journal-title":"Arch Osteoporos"},{"issue":"3","key":"5845_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00223-016-0141-7","volume":"99","author":"C Reyes","year":"2016","unstructured":"Reyes C, Pottegard A, Schwarz P, Javaid MK, Van Staa TP, Cooper C, Diez-Perez A, Abrahamsen B, Prieto-Alhambra D (2016) Real-life and RCT participants: alendronate users versus FITs\u2019 trial eligibility criterion. Calcif Tissue Int 99(3):243\u2013249. https:\/\/doi.org\/10.1007\/s00223-016-0141-7","journal-title":"Calcif Tissue Int"},{"issue":"42","key":"5845_CR10","doi-asserted-by":"publisher","first-page":"e12691","DOI":"10.1097\/MD.0000000000012691","volume":"97","author":"YK Wang","year":"2018","unstructured":"Wang YK, Zhang YM, Qin SQ, Wang X, Ma T, Guo JB, Zhu C, Luo ZJ (2018) Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 97(42):e12691. https:\/\/doi.org\/10.1097\/MD.0000000000012691","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"5845_CR11","doi-asserted-by":"publisher","first-page":"Cd001347","DOI":"10.1002\/14651858.CD001347.pub2","volume":"10","author":"CS Allen","year":"2016","unstructured":"Allen CS, Yeung JH, Vandermeer B, Homik J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database System Rev 10(10):Cd001347. https:\/\/doi.org\/10.1002\/14651858.CD001347.pub2","journal-title":"Cochrane Database System Rev"},{"issue":"10","key":"5845_CR12","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00198-013-2365-y","volume":"24","author":"KR Olsen","year":"2013","unstructured":"Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int 24(10):2639\u20132647. https:\/\/doi.org\/10.1007\/s00198-013-2365-y","journal-title":"Osteoporos Int"},{"key":"5845_CR13","doi-asserted-by":"publisher","first-page":"i3365","DOI":"10.1136\/bmj.i3365","volume":"353","author":"B Abrahamsen","year":"2016","unstructured":"Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365. https:\/\/doi.org\/10.1136\/bmj.i3365","journal-title":"BMJ"},{"issue":"6","key":"5845_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jamda.2016.12.083","volume":"18","author":"P Nordstrom","year":"2017","unstructured":"Nordstrom P, Toots A, Gustafson Y, Thorngren KG, Hommel A, Nordstrom A (2017) Bisphosphonate use after hip fracture in older adults: a Nationwide retrospective cohort study. J Am Med Dir Assoc 18(6):515\u2013521. https:\/\/doi.org\/10.1016\/j.jamda.2016.12.083","journal-title":"J Am Med Dir Assoc"},{"key":"5845_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11657-015-0235-2","volume":"10","author":"M Hoff","year":"2015","unstructured":"Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Abrahamsen B, Schei B (2015) Use of anti-osteoporotic drugs in Central Norway after a forearm fracture. Arch Osteoporos 10:235. https:\/\/doi.org\/10.1007\/s11657-015-0235-2","journal-title":"Arch Osteoporos"},{"issue":"8","key":"5845_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00198-018-4560-3","volume":"29","author":"M Hoff","year":"2018","unstructured":"Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Skovlund E, Abrahamsen B, Forsmo S, Schei B (2018) Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. Osteoporos Int 29(8):1875\u20131885. https:\/\/doi.org\/10.1007\/s00198-018-4560-3","journal-title":"Osteoporos Int"},{"issue":"3","key":"5845_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00228-009-0746-0","volume":"66","author":"HM Devold","year":"2010","unstructured":"Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol 66(3):299\u2013306. https:\/\/doi.org\/10.1007\/s00228-009-0746-0","journal-title":"Eur J Clin Pharmacol"},{"key":"5845_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"issue":"4","key":"5845_CR19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/ije\/dys095","volume":"42","author":"S Krokstad","year":"2013","unstructured":"Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, Bratberg G, Heggland J, Holmen J (2013) Cohort profile: the HUNT study, Norway. Int J Epidemiol 42(4):968\u2013977. https:\/\/doi.org\/10.1093\/ije\/dys095","journal-title":"Int J Epidemiol"},{"issue":"20","key":"5845_CR20","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2015.5161","volume":"313","author":"MR Blum","year":"2015","unstructured":"Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies C (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313(20):2055\u20132065. https:\/\/doi.org\/10.1001\/jama.2015.5161","journal-title":"JAMA"},{"issue":"1","key":"5845_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00198-019-05206-0","volume":"31","author":"M Hoff","year":"2020","unstructured":"Hoff M, Skovlund E, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Forsmo S, Abrahamsen B, Schei B (2020) Proton pump inhibitors and fracture risk. The HUNT study, Norway. Osteoporosis Int 31(1):109\u2013118. https:\/\/doi.org\/10.1007\/s00198-019-05206-0","journal-title":"Osteoporosis Int"},{"key":"5845_CR22","unstructured":"Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD) \u2013 new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiol 129\u2013136"},{"issue":"5","key":"5845_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44(5):734\u2013743. https:\/\/doi.org\/10.1016\/j.bone.2009.01.373","journal-title":"Bone"},{"issue":"10","key":"5845_CR24","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s00198-017-4134-9","volume":"28","author":"M Hoff","year":"2017","unstructured":"Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporos Int 28(10):2935\u20132944. https:\/\/doi.org\/10.1007\/s00198-017-4134-9","journal-title":"Osteoporos Int"},{"issue":"9","key":"5845_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/sim.4780120902","volume":"12","author":"SE Vollset","year":"1993","unstructured":"Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12(9):809\u2013824. https:\/\/doi.org\/10.1002\/sim.4780120902","journal-title":"Stat Med"},{"issue":"3","key":"5845_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/pds.2344","volume":"21","author":"HM Devold","year":"2012","unstructured":"Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ (2012) Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 21(3):297\u2013304. https:\/\/doi.org\/10.1002\/pds.2344","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"5845_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.clinthera.2015.05.505","volume":"37","author":"K Iglay","year":"2015","unstructured":"Iglay K, Cao X, Mavros P, Joshi K, Yu S, Tunceli K (2015) Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther 37(8):1813\u20131821.e1811. https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.505","journal-title":"Clin Ther"},{"issue":"9041","key":"5845_CR28","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535\u20131541. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Lancet"},{"issue":"5","key":"5845_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40266-016-0344-7","volume":"33","author":"EM van de Glind","year":"2016","unstructured":"van de Glind EM, Willems HC, Eslami S, Abu-Hanna A, Lems WF, Hooft L, de Rooij SE, Black DM, van Munster BC (2016) Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate. Drugs Aging 33(5):347\u2013353. https:\/\/doi.org\/10.1007\/s40266-016-0344-7","journal-title":"Drugs Aging"},{"issue":"6","key":"5845_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/joim.12700","volume":"282","author":"B Abrahamsen","year":"2017","unstructured":"Abrahamsen B (2017) The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old. J Intern Med 282(6):560\u2013562. https:\/\/doi.org\/10.1111\/joim.12700","journal-title":"J Intern Med"},{"issue":"5","key":"5845_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339(5):292\u2013299. https:\/\/doi.org\/10.1056\/NEJM199807303390502","journal-title":"N Engl J Med"},{"issue":"6","key":"5845_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00198-019-04906-x","volume":"30","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30(6):1145\u20131156. https:\/\/doi.org\/10.1007\/s00198-019-04906-x","journal-title":"Osteoporos Int"},{"issue":"10","key":"5845_CR33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s40265-019-01145-6","volume":"79","author":"HG Raterman","year":"2019","unstructured":"Raterman HG, Bultink IEM, Lems WF (2019) Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs 79(10):1065\u20131087. https:\/\/doi.org\/10.1007\/s40265-019-01145-6","journal-title":"Drugs"},{"issue":"3","key":"5845_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11926-012-0252-8","volume":"14","author":"IE Bultink","year":"2012","unstructured":"Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF (2012) Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep 14(3):224\u2013230. https:\/\/doi.org\/10.1007\/s11926-012-0252-8","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"5845_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1517\/14656566.2013.761975","volume":"14","author":"IE Bultink","year":"2013","unstructured":"Bultink IE, Baden M, Lems WF (2013) Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 14(2):185\u2013197. https:\/\/doi.org\/10.1517\/14656566.2013.761975","journal-title":"Expert Opin Pharmacother"},{"key":"5845_CR36","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE Levesque","year":"2010","unstructured":"Levesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087. https:\/\/doi.org\/10.1136\/bmj.b5087","journal-title":"BMJ"},{"issue":"10","key":"5845_CR37","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/jbmr.446","volume":"26","author":"DC Mackey","year":"2011","unstructured":"Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR, Cummings SR (2011) Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res 26(10):2411\u20132418. https:\/\/doi.org\/10.1002\/jbmr.446","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05845-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T14:07:20Z","timestamp":1623334040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05845-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5845"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05845-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"4 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}